Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRNA7 | P36544 | 1/20 | 0.40 |
| ▸ | HRH1 | P35367 | 1/20 | 0.38 |
| ▸ | CXCR4 | P61073 | 1/20 | 0.35 |
| ▸ | OPRM1 | P35372 | 2/20 | 0.34 |
| ▸ | OPRL1 | P41146 | 2/20 | 0.34 |
| ▸ | MAPK8 | P45983 | 1/20 | 0.33 |
| ▸ | MAPK9 | P45984 | 1/20 | 0.33 |
| ▸ | MAPK10 | P53779 | 1/20 | 0.33 |
| ▸ | IDH1 | O75874 | 1/20 | 0.33 |
| ▸ | HTT | P42858 | 1/20 | 0.32 |
| ▸ | PDE10A | Q9Y233 | 3/20 | 0.32 |
| ▸ | POLB | P06746 | 1/20 | 0.32 |
| ▸ | MAPT | P10636 | 1/20 | 0.32 |
| ▸ | APLNR | P35414 | 1/20 | 0.31 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.31 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.31 |
| ▸ | HPGD | P15428 | 1/20 | 0.31 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.31 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.31 |
| ▸ | KIF11 | P52732 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23325059 | 0.80 | OPRL1 (0.41) | HRH1OPRM1OPRL1HTTPOLB | |
| SCHEMBL30038147 | 0.78 | PDE10A (0.41) | HRH1HTTPDE10APOLBMAPT | |
| SCHEMBL13439542 | 0.76 | CHRNA7 (0.45) | CHRNA7CXCR4OPRM1OPRL1HPGD | |
| SCHEMBL2609321 | 0.75 | CHRNA7 (0.47) | CHRNA7CXCR4OPRM1OPRL1POLB | |
| SCHEMBL22315285 | 0.75 | OPRL1 (0.43) | CHRNA7OPRM1OPRL1PDE10AMAPK1 | |
| SCHEMBL12304132 | 0.74 | CHRNA7 (0.44) | CHRNA7CXCR4OPRM1OPRL1KDM4E | |
| SCHEMBL21974223 | 0.74 | CHRNA7 (0.44) | CHRNA7CXCR4OPRM1OPRL1KDM4E | |
| SCHEMBL21774648 | 0.73 | SLC6A3 (0.43) | IDH1PDE10AALDH1A1 | |
| SCHEMBL26049094 | 0.73 | SLC6A3 (0.33) | MAPK8MAPK9MAPK10IDH1PDE10A | |
| SCHEMBL9369196 | 0.73 | PDE10A (0.42) | HRH1MAPK8MAPK9MAPK10HTT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230374035-A1 | RAS INHIBITORS | Revolution Medicines, Inc. | 2023-11-23 | — | — | US | disclosed |
| US-20230374035-A1 | RAS INHIBITORS | Revolution Medicines, Inc. | 2023-11-23 | — | — | US | disclosed |
| US-20230234929-A1 | RAS INHIBITORS | WILMINGTON TRUST, NATIONAL ASSOCIATION, AS AGENT | 2023-07-27 | — | — | US | disclosed |
| US-20230234929-A1 | RAS INHIBITORS | WILMINGTON TRUST, NATIONAL ASSOCIATION, AS AGENT | 2023-07-27 | — | — | US | disclosed |
| US-20230233569-A1 | METHODS FOR DELAYING, PREVENTING, AND TREATING ACQUIRED RESISTANCE TO RAS INHIBITORS | WILMINGTON TRUST, NATIONAL ASSOCIATION, AS AGENT | 2023-07-27 | — | — | US | disclosed |
| US-20230233569-A1 | METHODS FOR DELAYING, PREVENTING, AND TREATING ACQUIRED RESISTANCE TO RAS INHIBITORS | WILMINGTON TRUST, NATIONAL ASSOCIATION, AS AGENT | 2023-07-27 | — | — | US | disclosed |
| US-11566007-B2 | Ras inhibitors | Revolution Medicines, Inc. (US) | 2023-01-31 | — | — | US | disclosed |
| US-20210130369-A1 | RAS INHIBITORS | WILMINGTON TRUST, NATIONAL ASSOCIATION, AS AGENT | 2021-05-06 | — | — | US | disclosed |
| US-20210130303-A1 | RAS INHIBITORS | WILMINGTON TRUST, NATIONAL ASSOCIATION, AS AGENT | 2021-05-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11566007-B2 | Ras inhibitors | KRAS, NRAS, HRAS | CHRNA7 4871/4885HRH1 2949/4885CXCR4 3632/4885 |
| US-20230234929-A1 | RAS INHIBITORS | KRAS, NRAS, HRAS | CHRNA7 4871/4885HRH1 2949/4885CXCR4 3632/4885 |
| US-20230233569-A1 | METHODS FOR DELAYING, PREVENTING, AND TREATING ACQUIRED RESISTANCE TO RAS INHIBITORS | KRAS, HRAS, MTOR | CHRNA7 4867/4885HRH1 3515/4885CXCR4 3801/4885 |
| US-20210130303-A1 | RAS INHIBITORS | KRAS, NRAS, HRAS | CHRNA7 4871/4885HRH1 2949/4885CXCR4 3632/4885 |
| US-20230374035-A1 | RAS INHIBITORS | KRAS, NRAS, HRAS | CHRNA7 4871/4885HRH1 2949/4885CXCR4 3632/4885 |
| US-20210130369-A1 | RAS INHIBITORS | KRAS, NRAS, HRAS | CHRNA7 4871/4885HRH1 2949/4885CXCR4 3632/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.